Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is characterised by chronic airflow limitation and persistent symptoms.[@CIT0001] COPD is mainly caused by tobacco smoking and is currently the third leading cause of death worldwide.[@CIT0001],[@CIT0002]

Chronic airway and lung inflammation are the main characteristics of the pathogenesis of COPD and are associated with a collapse of small airways, parenchymal destruction and goblet cell proliferation in bronchial epithelium.[@CIT0003] Moreover, it is known that COPD may be associated with systemic inflammation and comorbidities.[@CIT0004]

The natural course of COPD is altered by episodes of exacerbations characterised by an increase of both pulmonary and systemic inflammation.[@CIT0005] In the last years, there has been increasing interest in describing biomarkers that could help predict the occurrence of exacerbations of COPD (ECOPD) and the clinical evolution of COPD, and therefore, the use of these biomarkers could help in therapeutic decision making.[@CIT0006]

Some of the biomarkers proposed in stable and exacerbated COPD patients include neutrophil counts, C-reactive protein (CRP), tumor necrosis factor α, interleukin (IL) 6, IL-8 and fibrinogen.[@CIT0007],[@CIT0008] However, only fibrinogen has been accepted as a reliable biomarker for use in clinical trials because of its repeatability and correlation with variables of COPD severity and prognosis, although it is not a good predictor of the risk of ECOPD.[@CIT0009]

Recent studies have proposed the use of other markers obtained in routine blood analysis, such as the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR) and the eosinophil/basophil ratio (EBR), as markers of the risk and severity of ECOPD and as prognostic markers of hospital mortality due to ECOPD.[@CIT0010]--[@CIT0012]

The importance of the identification of routine blood test biomarkers lays in better characterisation of COPD patients and personalisation of the management of the disease. The aim of our study was to identify the possible associations between routine blood biomarkers and the frequency and severity of ECOPD in an international cohort of patients with COPD.

Methods {#S0002}
=======

This was an observational, cross-sectional, multicentre study performed in pneumology departments of four teaching hospitals in Spain, Italy, Slovenia and Bulgaria. We included ambulatory COPD patients of 40 years of age or older; current or former smokers with a smoking history of at least 10 pack-years and a post-bronchodilator FEV~1~ (forced expiratory volume in the first second)/FVC (forced vital capacity) ratio \< 0.7; and in stable state, at least 1 month following recovery from the last ECOPD. The exclusion criteria were the presence of another chronic respiratory disease (eg cystic fibrosis, severe bronchiectasis, cancer or restrictive lung disease) or systemic inflammatory disease and inability to complete the quality of life questionnaires. Patients were included consecutively if inclusion and exclusion criteria were fulfilled.

Variables {#S0002-S2001}
---------

Sociodemographic characteristics and clinical COPD data were collected from all the patients. Other variables were studied including spirometry, self-reported clinical symptoms (cough, expectoration, wheezing), and number of ECOPD in the previous 12 months collected from the clinical history, and the degree of dyspnoea assessed according to the modified Medical Research Council (mMRC) dyspnoea scale.[@CIT0013] The BODEx index[@CIT0014] (body mass index, airway obstruction, dyspnoea, severe exacerbations) was calculated,and the COPD Assessment Test (CAT)[@CIT0015] score was obtained.

Moderate ECOPD was defined as an acute increase in respiratory symptoms requiring ambulatory treatment with antibiotics and/or systemic corticosteroids. When the episode required treatment in a hospital setting or assistance in the emergency room for at least 24 hrs it was considered severe.[@CIT0006]

Firstly patients were divided into clinical phenotypes according to the GesEPOC criteria:[@CIT0016] 1) non-exacerbator (NE): patients with 0 or 1 ECOPD in the previous year; 2) exacerbator with emphysema (EE): patients presenting at least two ECOPD in the previous year and clinical/radiological or functional evidence of emphysema; 3) exacerbator with chronic bronchitis (ECB): exacerbators with cough and expectoration for at least 3 months of the year over two consecutive years; and 4) asthma--COPD overlap: patients with a concomitant diagnosis of asthma and/or blood eosinophilia ≥ 300 cells/µL.[@CIT0017]

Secondly, they were classified into 2 groups: exacerbators, defined as patients with ≥ 2 ambulatory exacerbations or 1 hospitalisation, or non-exacerbators defined as patients presenting ≤ 1 ambulatory exacerbation in the previous year. Finally, patients were classified according to the new Global Obstructive Lung Disease (GOLD) 2019 A-D classification.[@CIT0018]

Analysis of Biomarkers {#S0002-S2002}
----------------------

Routine blood analyses were performed during stable phase in all the patients. The following biomarkers were analysed: blood cell count, CRP, alpha1-antitrypsin (AAT) and fibrinogen. In addition, the following indices were calculated: the NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count, the EBR as the division between the absolute eosinophil count and the absolute basophil count, and finally, the PLR was defined as the platelet count divided by the absolute lymphocyte count.

Statistical Analysis {#S0002-S2003}
--------------------

Qualitative variables were described with absolute frequencies and percentages. The description of quantitative variables was performed using the mean, standard deviation (SD), median and quartiles. The Kolmogorov--Smirnov test was used to assess the normality of distributions.

The patient characteristics were compared according to the country, phenotype, the presence of previous ECOPD and GOLD A to D groups. In the case of quantitative variables, the Student's *t*-test (Mann--Whitney *U*-test if normality was not assumed) or ANOVA tests (in the case of country and phenotype) were carried out. The Chi-squared test (Fisher test for frequencies \<5) was used for the comparison of categorical variables.

A multivariate model was developed using backward stepwise logistic regression analysis including the presence of exacerbator phenotype as the dependent variable. Variables with a significance \<0.2 in the univariate analysis were included as independent variables. The results were described with odds ratios (OR), 95% confidence interval (CI) and p-values. For all the tests, p-values \< 0.05 were considered statistically significant. The statistical package SPSS (V 25) was used for the statistical analyses.

Results {#S0003}
=======

A total of 355 patients were included. The mean age (SD) was 66 years (8.9) and 64.5% were male. Thirty-three percent were active smokers with a mean tobacco consumption of 40.8 (25.9) pack-years. The mean degree of dyspnoea (mMRC) was 1.8 (1), and the mean post-bronchodilator FEV1% was 55% (19.9%). Patients had a mean CAT score of 15.6 (7.9) and a mean BODEx index of 2.7 (2). Regarding clinical phenotypes,181 (51%) patients were classified as NE, 73 (20.6%) as EE, 55 (15.5%) as ECB and 46 (13%) as ACO. The mean rates of moderate and severe exacerbations in the previous year were 0.8 (1.2) and 0.5 (0.9) respectively. The sociodemographic and clinical characteristics of the patients are shown in [Table 1](#T0001){ref-type="table"}.Table 1Sociodemographic and Clinical Characteristics of COPD Patients IncludedVariableGlobal (N=355)Spain (N=80)Italy (N=82)Slovenia (N=97)Bulgaria (N=96)\*p valueAge, years66.6 (8.9)65.9 (8.9)68.5 (10.3)67.1 (8.1)65.1 (8.1)0.065Sex, male (%)229 (64.5)57 (71.3)59 (72)53 (54.6)60 (62.5)0.049Ex-smokers (%)\
Pack-years (smokers/ex)233 (66.8)\
41 (26)60 (75)\
52 (32)51 (67.1)\
46 (28)61 (62.9)\
39 (22)61 (63.5)\
28 (15)0.314\
\<0.001BMI (kg/m^2^)25.8 (5)25.1 (5.4)26.1 (5.6)25.6 (4.6)26.3 (4.5)0.421mMRC1.8 (1)1.8 (0.9)2 (1)1.4 (1)2.1 (1)\<0.001Cough (%)240 (67.6)45 (56.3)50 (61)55 (56.7)90 (93.8)\<0.001Wheezing (%)140 (39.4)24 (30)26 (31.7)21 (21.6)69 (71.9)\<0.001Sputum (%)228 (64.4)45 (56.3)54 (65.9)61 (62.9)68 (71.6)0.201Dyspnoea (%)295 (83.1)64 (80)70 (85.4)82 (84.5)79 (82.3)0.793FVC (mL)2708 (956)2395 (922)2381 (715)3060 (962)2752 (1043)\<0.001FVC (%)67.9 (18.3)65.7 (18.4)76.8 (16.6)82.2 (19.3)66.4 (18.9)\<0.001FEV1 (mL)1475 (625)1253 (581)1518 (489)1567 (697)1525 (649)0.005FEV1 (%)55 (19.9)44.6 (16.4)62.8 (16.1)56.2 (21.6)55.8 (20.2)\<0.001FEV1/FVC54.2 (12.1)51.7 (10.2)60.5 (10.2)50.1 (13.1)55.7 (11.7)0.412Phenotypes(%)\
- NE\
- ACO\
- EE\
- ECB\
181 (51)\
46 (13)\
73 (20.6)\
55 (15.5)\
36 (45)\
8 (10)\
30 (37.5)\
6 (7.5)\
57 (69.5)\
7 (8.5)\
6 (7.3)\
12 (14.6)\
66 (68)\
18 (18.6)\
7 (7.2)\
6 (6.2)\
22 (22.9)\
13 (13.5)\
30 (31.3)\
31 (32.3)\
\<0.001BODEx index2.7 (2)3.3 (1.9)2.1 (1.5)1.9 (1.8)3.3 (2.1)\<0.001CAT15.6 (7.9)15 (7.9)17 (7.4)14.9 (6.6)15.6 (9.2)0.294Moderate exacerbations0.8 (1.2)1 (1.3)1.2 (1.5)0.5 (0.9)0.7 (0.8)\<0.001Severe exacerbations0.5 (0.9)0.7 (1)0.2 (0.5)0.1 (0.4)1.1 (0.9)\<0.001Leukocytes (x 10^3^ μL)8.4 (2.2)8.5 (2.4)8.1 (1.8)8.2 (2.1)8.6 (2.3)0.342Eosinophils (x 10^3^ μL)0.2 (0.4)0.3 (0.6)0.3 (0.3)0.2 (0.1)0.2 (0.2)0.196CRP (mg/dL)2.4 (3.3)0.9 (1.2)0.8 (1.1)1.5 (1.4)4.4 (4.2)\<0.001AAT (mg/dL)151 (34)151 (37)150 (48)159 (28)143 (25)0.013Fibrinogen (mg/dL)4.6 (13.2)7.2 (2.7)3.3 (0.9)3.9 (0.8)4 (1)0.269[^2]

Characteristics of Patients According to the Geographical Region {#S0003-S2001}
----------------------------------------------------------------

No significant differences were found in terms of age, number of active smokers, BMI or CAT scores ([Table 1](#T0001){ref-type="table"}). However, compared with patients from other countries, COPD patients in Spain had greater tobacco exposure (p\<0.001), more severely impaired lung function in terms of FEV1% (p\<0.001), a higher BODEx index and a higher rate of moderate ECOPD. A higher BODEx index was also observed in Bulgarian patients and more frequent moderate ECOPD in Italian patients. On the other hand, COPD patients in Bulgaria had a higher rate of severe ECOPD (p\<0.001) and higher CRP levels (p\<0.001) than patients from other countries ([Table 1](#T0001){ref-type="table"}).

Characteristics of Patients According to Clinical Phenotypes {#S0003-S2002}
------------------------------------------------------------

No significant differences were observed between clinical phenotypes in terms of age, sex or smoking history. However, COPD patients classified as ECB had a higher BMI (p\<0.001) and more frequent moderate ECOPD in the previous year than the remaining patients (p\<0.001). Regarding blood biomarkers, ECB patients presented higher CRP levels (p\<0.001) and NLR (p=0.024) but had a lower platelet count (p=0.018).

COPD patients classified as EE had a higher degree of dyspnoea (p\<0.001), higher BODEx (p\<0.001) and CAT scores (p\<0.001), a higher rate of ECOPD in the previous year (p\<0.001) and more severe lung function impairment (p\<0.001) than the remaining clinical phenotypes.

ACO patients presented a lower degree of dyspnoea and better FEV1% (p\<0.001) as well as a higher eosinophil count (p\<0.001), ELR (p=0.001) and EBR (p\<0.001) ([Table 2](#T0002){ref-type="table"}).Table 2Characteristics of the Patients According to the Clinical PhenotypeVariablesNon-Exacerbator (N= 181)ACO (N=46)Exacerbator with Emphysema (N=73)Exacerbator with Chronic Bronchitis (N= 55)\*p valueAge, years67.1 (8.3)65.5 (9.4)66.6 (8.2)65.9 (11)0.650Sex, male (%)122 (67.4)24 (52.2)47 (64.4)36 (65.5)0.291Ex smokers (%)\
Pack-years (smokers and ex)112 (63.3)\
44(27)34 (73.9)\
31 (22)56 (79.7)\
41 (23)31 (58.5)\
37 (27)0.074\
0.010BMI (kg/m^2^)25.5 (4.9)26.2 (4.8)24.2 (4.2)28.4 (5.8)\<0.001mMRC1.6 (0.9)1.5 (0.9)2.3 (0.9)2.1 (1)\<0.001FEV1 (%)57.8 (18.4)64.6 (16.1)39.3 (16.6)58.7 (20.5)\<0.001BODEx index2 (1.6)1.9 (1.5)4.6 (1.8)3.1 (1.7)\<0.001CAT14.1 (7.1)14.7 (7.5)18.4 (8.8)17.4 (7.9)\<0.001Moderate exacerbations0.4 (0.5)0.8 (1.2)1.5 (1.3)1.5 (1.6)\<0.001Severe exacerbations0.1 (0.2)0.6 (1)1.3 (1)1 (0.8)\<0.001Laboratory FindingsHaemoglobin (g/dL)14.5 (1.6)14.5 (1.2)14.2 (1.8)14.2 (1.7)0.511Haematocrit (%)44.2 (4.4)43.8 (4.1)44.3 (5.3)44.3 (5.6)0.937Platelets (x 10^3^ μL)252 (78)266 (62)262 (70)246 (64)0.018Fibrinogen (mg/dL)5.3 (18.9)3.7 (0.8)4 (1)4 (0.8)0.269CRP (mg/dL)1.6 (2.3)1.4 (1.4)3.1 (3.8)3.8 (4.5)\<0.001AAT (mg/dL)154 (35)141 (27)148 (37)154 (31)0.013Leukocyte (x 10^3^ μL)8.3 (2.3)8.2 (1.8)8.5 (2.3)8.5 (2)0.759Neutrophil (x 10^3^ μL)5.5 (4.1)6.2 (8.5)5.5 (1.9)5.4 (1.9)0.803Neutrophil (%)62.2 (9.5)59.6 (10.8)64 (9.7)62.5 (10.4)0.136Lymphocytes (x 10^3^ μL)2.4 (2.9)2.8 (3.8)2.1 (0.8)2.1 (0.7)0.506Lymphocytes (%)26.6 (8.4)27.8 (9.4)24.6 (8)26.1 (9)0.220Eosinophils (x 10^3^ μL)0.2 (0.2)0.5 (0.8)0.2 (0.2)0.2 (0.2)\<0.001Eosinophils (%)2.4 (1.7)3.8 (3)2.3 (1.9)2.5 (2)\<0.001NLR2.8 (1.6)2.7 (2)3.1 (1.7)3.4 (3.9)0.024ELR0.1 (0.1)0.2 (0.4)0.1 (0.1)0.1 (0.1)0.001EBR\
PLR4.2 (3.3)\
133 (71)8 (10)\
138 (87)3.4 (3.1)\
144 (59)3 (3)\
132 (76)\<0.001\
0.708Platelets (x 10^3^ μL)252 (72)266 (62)262 (70)246 (64)0.459[^3]

Routine Blood Biomarkers According to the Presence of Exacerbations and GOLD Groups {#S0003-S2003}
-----------------------------------------------------------------------------------

Out of 355 COPD patients, 196 (55.2%) were classified in the non-exacerbator group and 159 (44.8%) were classified as exacerbators. On comparing blood parameters between the two groups, we found that the exacerbators group presented lower haemoglobin levels (p=0.019) and EBR (p=0.023). In contrast, they presented higher CRP levels (p=0.001). [Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"} show the CRP levels and the EBR according to exacerbations, respectively. As for the rest of the biomarkers studied, we did not find significant differences between groups. When comparing between the GOLD groups, C and D patients presented higher levels of CRP (p\<0.05), and lower levels of AAT were observed in the group C (p\<0.05). No other significant differences were found in the rest of the studied biomarkers. Complete data are described in [Table 3](#T0003){ref-type="table"}.Table 3Blood Biomarkers According to Non-Exacerbator/Exacerbator Phenotype and GOLD GroupsLaboratory parametersNon- Exacerbators\
(N=196)Exacerbators\
(N=159)GOLD GroupsGroup A\
(N= 45)Group B\
(N= 148)Group C\
(N= 20)Group D\
(N= 142)Haemoglobin (g/dL)14.5 (1.5)14.2 (1.6)^a^14.6 (1.5)14.5 (1.6)14.8 (1.3)14.1 (1.7)Haematocrit (%)44 (4.6)44.2 (4.9)44.5 (4.4)44.1 (4.5)46.2 (3.8)43.8 (5.2)Platelets (x 10^3^ μL)251 (77)260 (66)261.6 (75)249.3 (79)245.3 (61)261.5 (67)Fibrinogen (mg/dL)3.8 (0.8)3.9 (0.9)4 (0.9)5.5 (2.8)3.8 (0.9)3.9 (0.9)CRP (mg/dL)1.6 (2.2)3.0 (3.9)^b^1.4 (1.6)1.7 (2.5)2.8 (3.2)3 (3.9)^c^AAT (mg/dL)153 (34)149 (33)144.9 (34)155.6 (35)134 (34)152 (33)^c^Leukocyte (x 10^3^ μL)8.3 (2.2)8.4 (2.1)8.2 (2)8.3 (2.3)8.2 (2.1)8.4 (2.1)Neutrophil (x 10^3^ μL)5.7 (2.7)5.3 (1.8)5.1 (1.7)6 (6.5)5.1 (1.6)5.4 (1.9)Lymphocyte (x 10^3^ μL)2.5 (3.3)2.1 (0.7)2.1 (0.6)2.6 (3.9)2.2 (0.8)2.1 (0.7)Eosinophils (x 10^3^ μL)0.2 (0.4)0.2 (0.2)0.2 (0.2)0.3 (0.5)0.2 (0.2)0.2 (0.2)Eosinophils (%)2.4 (1.8)2.7 (2.3)2.7 (1.4)2.4 (1.9)2.6 (2.2)2.7 (2.3)Basophil (x 10^3^ μL)0.5 (0.8)0.5 (0.5)0 (0)0.1 (0.1)0.1 (0.1)0 (0)NLR2.8 (1.6)3.0 (2.7)2.6 (1.1)2.9 (1.8)2.8 (1.5)3.1 (2.8)ELR0.1 (0.2)0.1 (0.1)0.1 (0.1)0.1 (0.2)0.1 (0.1)0.1 (0.1)EBR5.0 (6.1)3.6 (3.1)^a^5.6 (5.9)4.9 (6.2)3 (2.4)3.7 (3.2)PLR134 (72)141 (72)134.1 (62)131.9 (76)128.9 (53)142.3 (74)[^4] Figure 1C- reactive protein (CRP) in exacerbators and non-exacerbators.**Notes:** Non-exacerbators: patients with ≤ 1 ambulatory exacerbation in the previous year; Exacerbators: patients with ≥ 2 ambulatory exacerbations or 1 hospitalisation in the previous year.**Abbreviation:** CRP, C-reactive protein.Figure 2Eosinophil/basophil ratio (EBR) in exacerbators and non-exacerbators.**Notes:** Non-exacerbators: patients with ≤ 1 ambulatory exacerbation in the previous year; Exacerbators: patients with ≥ 2 ambulatory exacerbations or 1 hospitalisation in the previous year.

Multivariate Analysis to Determine Factors Associated with Exacerbations {#S0003-S2004}
------------------------------------------------------------------------

Multivariate analysis showed that females (OR=5, p=0.002), high levels of CRP (OR=1.35, p=0.049), a lower FEV1% (OR=0.92, p=0.008) and a low EBR (OR=0.489, p=0.002) were significantly and independently related to being an exacerbator ([Table 4](#T0004){ref-type="table"}).Table 4Univariate and Multivariate Logistic Regression Analyses to Determine Factors Associated with ExacerbationsVariableUnivariateMultivariateOdds Ratio (95% Confidence Interval)p valueOdds Ratio (95% Confidence Interval)p valueAge0.98 (0.96--1.01)0.248----Sex (female)1.33 (0.85--2.04)0.2155 (1.17--8.33)0.002Pack-years0.99 (0.98--1.00)0.041----mMRC1.70 (1.35--2.13)\<0.001----CAT score1.06 (1.03--1.09)\<0.001----FEV1%0.97 (0.96--0.99)\<0.0010.92 (0.89--0.98)0.008Laboratory parameters: White blood cellsHaemoglobinPlateletsFibrinogenCRPAATNLRELREBRPLR\
1.03 (0.94--1.14)\
0.98 (0.97--1.00)\
1.00 (0.99--1.005)\
1.19 (0.93--1.54)\
1.18 (1.06--1.30)\
0.99 (0.99--1.00)\
1.06 (0.96--1.18)\
0.86 (0.20--3.68)\
0.92 (0.85--0.99)\
1.00 (0.99--1.01)\
0.486\
0.077\
0.274\
0.157\
0.002\
0.266\
0.254\
0.845\
0.048\
0.298\
--\
--\
--\
--\
1.35 (1.01--1.83)\
--\
--\
--\
0.48 (0.31--0.76)\
--\
--\
--\
--\
0.049\
--\
--\
--\
0.002[^5]

Discussion {#S0004}
==========

COPD is a chronic respiratory disease that is associated with systemic inflammation,[@CIT0004] and increased systemic inflammation may be associated with a higher risk of exacerbations and more or more severe comorbidities.[@CIT0004] Exacerbations play an important role in the natural history of COPD, being one of the main causes of mortality.[@CIT0019] Nowadays, the best predictor of ECOPD is having a history of previous ECOPD,[@CIT0020],[@CIT0021] and there are still no validated biomarkers to help recognize the frequent exacerbator phenotype of COPD. The identification of easy-to-obtain systemic biomarkers associated with frequent exacerbations may help physicians to identify at risk COPD patients and take adequate preventive measures. In this context, we analysed data from this multicentre and international study in order to identify the possible associations of different routine blood test biomarkers with the history of ECOPD and clinical phenotypes.

In our cohort, patients with exacerbations presented lower levels of haemoglobin and EBR and higher levels of CRP. Moreover, in the multivariate analysis, females, a more impaired FEV1%, higher levels of CRP and a lower EBR were variables independently and significantly associated with exacerbations.

Low haemoglobin concentrations are commonly observed in COPD patients and have been studied as a prognostic factor in this disease.[@CIT0022],[@CIT0023] As an example, several studies have observed that presenting low haemoglobin concentrations during admission due to ECOPD is related to increased mortality after discharge.[@CIT0024]--[@CIT0026] In the present study, patients reporting at least two ECOPD or one hospitalisation in the previous year had significantly lower haemoglobin concentrations, although haemoglobin was not identified as an associated independent factor in the multivariate analysis.

Regarding inflammatory blood biomarkers, we found higher CRP concentrations in patients with more exacerbations, especially in those with chronic bronchitis. CRP is the prototypical acute-phase reactant and is a useful biomarker to detect infection and tissue injury. CRP has been used to control the progression of chronic diseases such as inflammatory rheumatoid diseases and as a biomarker of future cardiovascular events.[@CIT0027] In COPD, previous studies have described elevated CRP levels as a good predictor for readmission and a marker of poor outcome after an ECOPD.[@CIT0028],[@CIT0029] Elevated baseline CRP levels have also been associated with higher mortality,[@CIT0030] and together with a high fibrinogen and leukocyte count were also associated with increased risk of having exacerbations.[@CIT0031]

In addition, AAT levels were lower in ACO and EE. Higher AAT and CRP levels have shown to be associated with an increased risk of COPD in the general population without AAT deficiency;[@CIT0032],[@CIT0033] however, the reduced levels of AAT observed in ACO patients have not been described previously.[@CIT0034],[@CIT0035]

Eosinophils are end-stage cells produced under the influence of macrophage colony-stimulating factor, interleukin (IL)-3 and the late differentiation factor IL-5.[@CIT0036] Non eosinophilic exacerbations in COPD are related to more severe infections and a higher hospital stay.[@CIT0037] On the other hand, basophils are related to inflammatory responses in immune diseases.[@CIT0038] The use of EBR as a biomarker in COPD was previously described by Xiong et al,[@CIT0012] who demonstrated that a higher EBR was associated with a lower rate of exacerbations and better survival. In accordance these results, a lower EBR was observed in our patients with frequent exacerbations. As expected, the highest EBR was observed in patients with ACO, who also had higher eosinophil levels, suggesting that increased eosinophilic inflammation in COPD is a marker of better prognosis compared with other phenotypes of the disease.[@CIT0011],[@CIT0034]

In contrast to previous data, we could not replicate the relationship found between some other biomarkers and exacerbations. In our study, neither the NLR nor the PLR or platelet count, were significantly elevated in patients with a history of exacerbations. However, the NLR was significantly elevated if the exacerbators had the chronic bronchitis phenotype. In contrast, exacerbators with emphysema showed a higher but non-significant PLR.

Elevated NLRs have been associated with the risk of exacerbations in previous studies, although no differences between different types of exacerbators (i.e chronic bronchitic, emphysematous or ACO) were reported.[@CIT0039],[@CIT0040] An elevated platelet count has been described to be associated with worse COPD morbidity, more severe lung function impairment, a higher likelihood of presenting ECOPD[@CIT0041] and with increased mortality during an exacerbation.[@CIT0042] Similarly, an elevated PLR has been proposed as a useful marker for increased risk of exacerbations and mortality after discharge for an ECOPD.[@CIT0043]--[@CIT0045]

Some of the differences observed in the associations between biomarkers and exacerbations between our study and previous studies may be related to the inclusion criteria. Most of the previous studies included patients during an ambulatory or hospital ECOPD, and therefore, significantly increased inflammatory biomarkers would be expected. In our study, the patients were included during a stable state and associations between the serum concentrations of biomarkers with a previous history of ECOPD were analysed. Although this interference was eliminated from our study by including only stable patients, it cannot be ruled out that patients with frequent exacerbations and chronic bronchitis may have chronic colonization and this might explain some elevated biomarkers, such as CRP.

The main limitation of our study was the cross-sectional design that did not allow analysis of the prognostic value of the biomarkers, but rather, only the associations. Therefore, it would be necessary to evaluate these biomarkers as prognostic factors in a study with a prospective design, including populations with patients with different degrees of disease severity and better characterization in terms of bronchial colonization and CT scan evidence of emphysema or bronchiectasis.

In conclusion, together with female sex and having a lower FEV1, higher CRP levels and a lower EBR were associated with a higher rate of exacerbations in COPD. If confirmed in prospective studies, these routine blood biomarkers can be useful for physicians to detect patients at high risk of presenting exacerbations.
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